Onco Wiki / drapeau rouge

Historique de transplantation de cellules souches autologues (ASCT) comme consolidation ou récupération de thérapeu...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-IATROGENIC-ASCT-SECONDARY-MDS-AML-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-20 | pending_clinical_signoff
MaladiesDIS-AML DIS-MDS-HR
SourcesSRC-COG-LTFU-V5-2018 SRC-EINHORN-HDCT-ASCT-2007 SRC-NCCN-AML-2025

Origine du drapeau rouge

DéfinitionHistory of autologous stem-cell transplantation (ASCT) as consolidation or salvage therapy for a previously-treated hematologic or lymphoid malignancy (multiple myeloma, Hodgkin lymphoma, non- Hodgkin lymphoma, germ-cell tumor salvage, etc.). ASCT survivors carry a 10-year cumulative risk of therapy-related myelodysplastic syndrome (t-MDS) / therapy-related AML (t-AML) of approximately 1-5%, with risk dominated by the cumulative pre-ASCT alkylator dose and the conditioning-regimen-related additional alkylator exposure (high-dose melphalan in MM, BEAM in lymphoma, etc.). Median latency 3-7 years post-ASCT; risk plateaus by 10 years but does not return to baseline. Distinct from RF-IATROGENIC-ALKYLATOR-TAML-PREVENTION (general alkylator-exposure RF) by virtue of identifying the specific ASCT-survivor cohort which has documented higher absolute risk than alkylator-exposure-without-ASCT coh...
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "prior_autologous_stem_cell_transplant_asct",
      "value": true
    },
    {
      "finding": "prior_asct_for_multiple_myeloma",
      "value": true
    },
    {
      "finding": "prior_asct_for_lymphoma",
      "value": true
    },
    {
      "finding": "prior_asct_for_germ_cell_tumor_salvage",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

v0.3 wave-N niche pathway — ASCT-survivor t-MDS/t-AML prevention. Fires on documented history of autologous stem-cell transplantation in a prior hematologic / lymphoid malignancy (multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, primary CNS lymphoma, germ- cell tumor salvage). The pre-ASCT cytotoxic exposure plus the high-dose-conditioning regimen (melphalan in MM, BEAM in lymphoma, CBV or carboplatin/etoposide/ifosfamide in salvage settings) drive bone-marrow stress and clonal-hematopoiesis emergence that predisposes to t-MDS / t-AML over the subsequent decade. Engine routes to PreventionPlan recommending: (a) IND-ASCT-SECONDARY-MDS-AML-PREVENTION-SURVEILLANCE (standard) — CBC with differential q3-6 months for the first 10 years post-ASCT, then q12mo lifelong; low-threshold marrow evaluation for any unexplained cytopenia, persistent macrocytosis (MCV >100), dysplastic peripheral smear, or unexplained monocytosis; clonal hematopoiesis-of-indeterminate- potential (CHIP) screening + risk-stratification where available; avoid additional bone-marrow-toxic exposures (additional alkylator-based therapy, benzene exposure); allogeneic HSCT eligibility pre-assessment so that if t-...

Utilisé par

Indication